Intelgenx Technologies
Description IntelGenx Technologies Corp., a drug delivery company, engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its product portfolio comprises INT0001/2004 for coronary heart failure and hypertension; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2007 for the treatment of migraine; INT0020/2010 for the treatment of insomnia; INT0024/2010 for idiopathic pulmonary fibrosis; INT0028/2011 for cancer pain; INT0030/2011 for animal health; and INT0031/2012 for the treatment of benign prostatic hyperplasia, as well as INT0027/2011, an oral controlled-release film product. The company develops its products based on three delivery platform technologies, which consist of the Multilayer Tablet technology that allows for the development of oral controlled-release products; the Oral Film technology, which allows for the delivery of pharmaceuticals to the oral cavity; and the Mucoadhesive Tablet technology for the controlled release of active substances to the oral mucosa. It also provides product development services for the pharmaceutical industry, including the branded and generic pharmaceutical markets. The company has a strategic alliance with LTS Lohmann Therapie-Systeme AG to manufacture pharmaceutical products using VersaFilm drug delivery technology. IntelGenx Technologies Corp. also has a co-development and commercialization agreement with RedHill Biopharma Ltd. for the co-development and commercialization of INT0008/2007. IntelGenx Technologies Corp. was founded in 2003 and is based in Ville Saint Laurent, Canada. To view the detailed information, you need to SUBSCRIBE with us. |
 |